 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF announced it had confirmed the bioavailability of its lead compound BETR-001 in the brain tissue and plasma of treated mice. BETR-001 is a non-hallucinogenic derivative of psychedelic drug LSD that BetterLife is developing to treat neuro-psychiatric and neurological disorders. 